AstraZeneca CEO Pascal Soriot urges Western drugmakers to adopt 'Chinese speed' to avoid falling behind in pharmaceutical innovation, as the industry faces rising competition from China.
The Call for Faster Innovation
Speaking from the company's Cambridge headquarters, Soriot emphasized that pharmaceutical companies in the US and Europe must accelerate their research and development cycles. "What we are learning ourselves is we have to move much faster. We always talk about Chinese speed in our company, and we want to operate in Chinese speed," he said.
Get the #1 Wireless Door Camera
REOLINK Bestseller: 2K Weatherproof Video Doorbell, No Monthly Fees.
AstraZeneca, a FTSE 100 giant, reported revenues of £30.7 billion in the first half of 2026—a 6% increase. The company targets $80 billion in annual sales by 2030, up from $59 billion last year. Soriot expressed confidence despite the recent failure of Wainua, a major heart disease drug in clinical trials.
Lessons from the Automotive Industry
Soriot drew a stark comparison to the automotive sector, where Western manufacturers focused on petrol engines while Chinese companies dominated electric vehicles. "Chinese companies were focused completely on electric vehicles and batteries," he noted. This serves as a cautionary tale for drugmakers.
Key Differences in Innovation Speed
| Area | Western Pharma | Chinese Pharma |
|---|---|---|
| R&D Cycle | 8-12 years | 4-6 years |
| Regulatory Approval | Longer timelines | Faster pathways |
| Focus Areas | Broad portfolio | Targeted generics & biologics |
AstraZeneca's Growth Strategy
Despite setbacks, Soriot highlighted an "unmatched" drug pipeline. Collaboration with Chinese partners remains key—AstraZeneca already works with local firms to bring drugs to global markets. "We have to accept to fail some of the time. Biology is biology," he said, referencing clinical trial risks.
- Prioritize speed in drug development
- Embrace collaborations with Chinese innovators
- Invest in next-generation therapies like gene editing
- Learn from cross-industry examples (e.g., automotive)
FAQ
What does 'Chinese speed' mean in pharma?
It refers to the accelerated pace of drug development and regulatory approval in China, often completing clinical trials and market entry in half the time of Western counterparts.
How is AstraZeneca adapting?
The company is collaborating with Chinese biotechs, adopting faster trial designs, and restructuring internal processes to match the agility of its Eastern competitors.
What industries face similar disruption?
The automotive sector is a prime example, where Western incumbents lost EV leadership to Chinese firms. Pharma must avoid a similar fate by innovating rapidly.
As the global pharmaceutical landscape shifts, Soriot's message is clear: Western drugmakers must rethink their timelines. The 'Chinese speed' approach may become a necessary blueprint for survival and growth in the coming decade.
Home Decor Shop
Acacia frida deluxe solid wood bed frame |
Bedroom bench |
Bed chest drawers |
Lingerie dresser |
Frame base |
Mirror with jewelry storage |
30 Bathroom Vanity |
Memory foam queen mattress |
Mattresses for back pain |
Nightstand set of 2 |
Grand Goldman Shop |
Civil Lawyer
Deutschland Trikot WM 2026
